About AADI Bioscience
Aadi Bioscience Inc. (Aadi) is a rapidly growing biopharmaceutical company focused on developing and commercializing precision medicines targeted to rare genomic alteration-driven cancers. Aadi’s leading asset, FYARRO™ (sirolimus albumin-bound nanoparticles for injectable suspension), targets cancers driven by mTOR pathway activation, including advanced malignant PEComa, a rare type of sarcoma, and TSC1/2alterations in a tumor-agnostic setting. Aadi is poised to take its precision medicine approach to market with the support of a world-class team that shares its deep passion for scientific innovation and commitment to improving patient outcomes in rare oncological disorders.
Aadi Bioscience is proud to be an Equal Employment Opportunity employer committed to a diverse and dynamic workplace. We do not discriminate based upon race, religion, color, national origin, gender (including pregnancy, childbirth, or related medical conditions), sexual orientation, gender identity, gender expression, age, status as a protected veteran, status as an individual with a disability, or other applicable legally protected characteristics.
About Our Culture
We believe in thinking big without compromising attention to detail, being graceful under pressure, and willing to roll up our sleeves to get things moving. A collaborative mindset, natural curiosity, and humble attitude are critical to our corporate culture and the key to our success.